Structural basis of valmerins as dual inhibitors of GSK3β/CDK5

被引:30
|
作者
Li, Xiaolong [1 ]
Wang, Xiaowei [2 ]
Tian, Zibin [2 ]
Zhao, Houling [1 ]
Liang, Da [1 ]
Li, Weisong [1 ]
Qiu, Yujin [1 ]
Lu, Shaoyong [3 ]
机构
[1] Weifang Med Univ, Affiliated Hosp, Depatment Spinal Surg, Weifang 261000, Peoples R China
[2] Qingdao Univ, Coll Med, Affiliated Hosp, Dept Gastroenterol, Qingdao 266003, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med, Med Bioinformat Ctr, Shanghai 200025, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
GSK3; beta/CDK5; MD simulation; Molecular docking; MM-PBSA; PCA; MOLECULAR-DYNAMICS SIMULATION; CANCER-THERAPY; KINASE; MECHANISM; BINDING; RESISTANCE; MUTATION; MUTANTS;
D O I
10.1007/s00894-014-2407-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Development of multi-target drugs is becoming increasingly attractive in the repertoire of protein kinase inhibitors discovery. In this study, we carried out molecular docking, molecular dynamics simulations, molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) binding free energy calculations, principal component analysis (PCA), and dynamical cross-correlation matrices (DCCM) to dissect the molecular mechanism for the valmerin-19 acting as a dual inhibitor for glycogen synthase kinase 3 beta (GSK3 beta) and cyclin-dependent kinase 5 (CDK5). Detailed MM-PBSA calculations revealed that the binding free energies of the valmerin-19 to GSK3 beta/CDK5 were calculated to be -12.60 +/- 2.28 kcal mol(-1) and -11.85 +/- 2.54 kcal mol(-1), respectively, indicating that valmerin-19 has the potential to act as a dual inhibitor of GSK3 beta/CDK5. The analyses of PCA and DCCM results unraveled that binding of the valmerin-19 reduced the conformational dynamics of GSK3 beta/CDK5 and the valmerin-19 bound to GSK3 beta/CDK5 might occur mostly through a conformational selection mechanism. This study may be helpful for the future design of novel and potent dual GSK3 beta/CDK5 inhibitors.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 50 条
  • [1] Structural basis of valmerins as dual inhibitors of GSK3β/CDK5
    Xiaolong Li
    Xiaowei Wang
    Zibin Tian
    Houling Zhao
    Da Liang
    Weisong Li
    Yujin Qiu
    Shaoyong Lu
    Journal of Molecular Modeling, 2014, 20
  • [2] Novel optimization of valmerins (tetrahydropyrido[1,2-a] isoindolones) as potent dual CDK5/GSK3 inhibitors
    Ouach, Aziz
    Boulahjar, Rajaa
    Vala, Christine
    Bourg, Stephane
    Bonnet, Pascal
    Guguen-Guillouzo, Christiane
    Ravache, Myriam
    Le Guevel, Remy
    Lozach, Olivier
    Lazar, Said
    Troin, Yves
    Meijer, Laurent
    Ruchaud, Sandrine
    Akssira, Mohamed
    Guillaumet, Gerald
    Routier, Sylvain
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 115 : 311 - 325
  • [3] Potentiation of Tau Aggregation by cdk5 and GSK3β
    Lee, Sangmook
    Hall, Garth F.
    Shea, Thomas B.
    JOURNAL OF ALZHEIMERS DISEASE, 2011, 26 (02) : 355 - 364
  • [4] Divergent roles of GSK3 and CDK5 in APP processing
    Ryder, J
    Su, YA
    Liu, F
    Li, BL
    Zhou, Y
    Ni, BH
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 312 (04) : 922 - 929
  • [5] Cdk5 and GSK3β inhibit fast endophilin-mediated endocytosis
    Ferreira, Antonio P. A.
    Casamento, Alessandra
    Roas, Sara Carrillo
    Halff, Els F.
    Panambalana, James
    Subramaniam, Shaan
    Schutzenhofer, Kira
    Hak, Laura Chan Wah
    McGourty, Kieran
    Thalassinos, Konstantinos
    Kittler, Josef T.
    Martinvalet, Denis
    Boucrot, Emmanuel
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [6] Cdk5 and GSK3β inhibit fast endophilin-mediated endocytosis
    Antonio P. A. Ferreira
    Alessandra Casamento
    Sara Carrillo Roas
    Els F. Halff
    James Panambalana
    Shaan Subramaniam
    Kira Schützenhofer
    Laura Chan Wah Hak
    Kieran McGourty
    Konstantinos Thalassinos
    Josef T. Kittler
    Denis Martinvalet
    Emmanuel Boucrot
    Nature Communications, 12
  • [7] Crosstalk between Cdk5 and GSK3β: implications for Alzheimer's disease
    Engmann, Olivia
    Giese, Karl Peter
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2009, 2
  • [8] Designing of dual inhibitors for GSK-3β and CDK5: Virtual screening and in vitro biological activities study
    Xie, Hongbo
    Wen, Haixia
    Zhang, Denan
    Liu, Lei
    Liu, Bo
    Liu, Qiuqi
    Jin, Qing
    Ke, Kehui
    Hu, Ming
    Chen, Xiujie
    ONCOTARGET, 2017, 8 (11) : 18118 - 18128
  • [9] CDK5 activator protein p25 preferentially binds and activates GSK3β
    Chow, Hei-Man
    Guo, Dong
    Zhou, Jie-Chao
    Zhang, Guan-Yun
    Li, Hui-Fang
    Herrup, Karl
    Zhang, Jie
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (45) : E4887 - E4895
  • [10] Dual Inhibition of GSK3β and CDK5 Protects the Cytoskeleton of Neurons from Neuroinflammatory-Mediated Degeneration In Vitro and In Vivo
    Reinhardt, Lydia
    Kordes, Susanne
    Reinhardt, Peter
    Glatza, Michael
    Baumann, Matthias
    Drexler, Hannes C. A.
    Menninger, Sascha
    Zischinsky, Gunther
    Eickhoff, Jan
    Froeb, Claudia
    Bhattarai, Prabesh
    Arulmozhivarman, Guruchandar
    Marrone, Lara
    Janosch, Antje
    Adachi, Kenjiro
    Stehling, Martin
    Anderson, Eric N.
    Abo-Rady, Masin
    Bickle, Marc
    Pandey, Udai Bhan
    Reimer, Michell M.
    Kizil, Caghan
    Schoeler, Hans R.
    Nussbaumer, Peter
    Klebl, Bert
    Sterneckert, Jared L.
    STEM CELL REPORTS, 2019, 12 (03): : 502 - 517